NUCLEOLIN and cancer: The nucleolin-binding aptamer was used to target a broad range of biological agents to tumor-bearing mice and human tumor cells in vitro, and was used in clinical trials of cancer patients as a cytotoxic agent, administered at doses that were 10–100 higher than the doses used in our murine studies, without inducing significant toxicities17.